Beyond Achondroplasia

Growing together with Clara

August 4, 2015
by inesp.alves

BMN-111 Phase 3 ancillary cohort

BioMarin press release 3rd August 2015 “A major event in the second quarter of BioMarin Pharmaceutical Inc. was the completion and results of the Phase 2 study with vosoritide (future BMN-111 commercial designation) for the treatment of achondroplasia. BioMarin related that … Continue reading

January 20, 2015
by inesp.alves
1 Comment

BMN-111 clinical trial update

Recently, I had valid information that BioMarin announced that the measurement study is now open for recruitment again for the multicenter study. However, BioMarin didn´t change the age requirement, so children still need to be 4.5 years or older. The person … Continue reading

September 18, 2013
by inesp.alves

BMN-111 going forward!!!

17 Sep 2013  BioMarin Provides Highlights Ahead of Research and Development Day BMN 111 for the Treatment of Achondroplasia   The company announced today that based on recent meetings with the FDA and the Medicines and Healthcare Products Regulatory Agency … Continue reading

Translate »